🇺🇸 FDA
Patent

US 11246871

Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias

granted A61KA61K31/198A61K31/519

Quick answer

US patent 11246871 (Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias) held by Northwestern University expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Northwestern University
Grant date
Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/198, A61K31/519, A61K31/522, A61K31/5377